Celldex’s Barzolvolimab Fails Phase 2 Prurigo Nodularis Trial Despite Mast Cell Depletion — Celldex Therapeutics, Inc.

Event summary

Phase 2 trial of barzolvolimab in prurigo nodularis (PN) failed to meet primary and key secondary endpoints.
Study showed profound mast cell depletion but no improvement in itch or skin lesions compared to placebo.
Barzolvolimab demonstrated a favorable safety profile with a new 450mg loading dose and up to 300mg Q4W regimen.
Celldex plans to discontinue the PN study and focus on other indications, including Phase 3 trials for CSU expected in Sept/Oct 2026.

The big picture

Celldex’s failure in the PN trial highlights the challenges of targeting mast cells in diverse inflammatory diseases. The company’s focus on CSU and ColdU, where barzolvolimab has shown promising results, will be critical for its strategic pivot. The biotech sector continues to grapple with high-risk, high-reward drug development, where even novel mechanisms like mast cell depletion can face unexpected hurdles.

What we're watching

Pipeline Focus: Whether Celldex can successfully pivot to other indications like chronic spontaneous urticaria (CSU) and cold urticaria (ColdU).
Execution Risk: The pace at which Celldex can generate positive data from its ongoing Phase 3 trials in CSU and ColdU.
Market Dynamics: How investors will react to the setback in PN while awaiting topline data from other barzolvolimab studies.